T

Tango Therapeutics

Develops synthetic-lethality cancer therapies

Senior Vice President - Market Access

Marketing Generalist & ManagementConfirmed live in the last 24 hours
Full-timeBoston, MA, USA$337.6k - $506.4k

About the Job

Requirements

  • A bachelor's degree is required; an advanced degree (MBA, PharmD, MPH, or related discipline) is strongly preferred.
  • At least 20 years of progressive biopharmaceutical experience, including significant executive-level experience in market access, pricing, and commercial strategy roles.
  • Demonstrated enterprise leadership experience transitioning companies through critical inflection points, such as moving from clinical-stage to commercial-stage.
  • A proven track record of architecting and leading successful U.S. market access launches for novel oral oncology or rare disease therapies.
  • Deep understanding of complex oral oncology treatment paradigms, pharmacy benefit designs, and the financial mechanics of specialty distribution and pharmacy benefit manager negotiations.
  • Exceptional ability to recruit, develop, and inspire a diverse team of senior functional leaders.
  • Highly developed communication and negotiation skills, with the ability to influence corporate boards, C-level peers, and external payer and channel partners.
  • Advanced capability in modeling complex gross-to-net scenarios, managing high-stakes contract strategies, and aligning access operations with corporate financial goals.

Responsibilities

  • Design, build, and scale an integrated market access organization capable of supporting multiple oral oncology product launches.
  • Lead, empower, and mentor a leadership team across global value and access, health economics and outcomes research, strategic operations, patient services, trade operations, and payer strategy.
  • Serve as the strategic anchor for market access across the C-suite and enterprise, embedding value demonstration, pricing elasticity, and payer insights into early-stage asset development and commercial strategy.
  • Direct the strategic generation of health economics and outcomes research to support evidence-based value narratives for health technology assessments and global payers.
  • Oversee the integration of U.S. and ex-U.S. access strategies for cohesive global value demonstration and market entry.
  • Formulate launch pricing, gross-to-net strategies, and contracting frameworks to position products across Commercial, Medicare Part D, and Medicaid segments.
  • Anticipate healthcare policy developments, including Medicare Part D redesigns and pharmacy benefit manager legislation, and steer corporate strategy to mitigate risks and capitalize on market shifts.
  • Forecast the structural impacts of federal pricing programs and align government pricing and access strategies with long-term portfolio revenue goals.
  • Design a scalable specialty pharmacy and distribution network for oral oncology therapeutics, balancing network control with broad community oncology access.
  • Define the vision for patient services and hub infrastructure, developing strategies to reduce access friction, optimize time-to-therapy, and improve patient experience.

Desired Qualifications

  • An advanced degree (MBA, PharmD, MPH, or related discipline) is strongly preferred.

About the Company

Tango Therapeutics

Develops synthetic-lethality cancer therapies

Tango Therapeutics develops cancer medicines by leveraging synthetic lethality to selectively kill cancer cells while sparing healthy cells. Its approach focuses on creating drugs that exploit interactions between gene pairs, aiming for targeted therapies that spare normal tissue. The company advances its treatments through a strong R&D program and collaborates with larger pharmaceutical partners, such as Gilead Sciences, to co-develop therapies and accelerate commercialization. Revenue comes from these partnerships and funding rounds like its Series B. Tango differentiates itself with a dedicated emphasis on genetically targeted cancer therapies, a robust pipeline, and leadership that guides strategic collaborations. The company’s goal is to bring next-generation, genetically targeted immunotherapies to market, improving outcomes for cancer patients by precisely targeting tumor biology.

Company size
51-200
Company stage
IPO
Headquarters
Boston, MA
Founded
2017

Recently Posted Jobs

Explore more opportunities at Tango Therapeutics

See more jobs